BOWLING GREEN, Ohio, Sept. 24, 2018 /PRNewswire/ -- Grifols is
pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East
Wooster Street, Bowling Green, Ohio. The 13,000 square foot state-of-the-art facility officially
opened its doors for business on September 17th, 2018 and brings the total number of
BPC's plasma collection centers to 23.
Ileana Carlisle, BPC's Chief Executive Officer and President, said "We are pleased to have
recently joined the Grifols Company, and look forward to being an active member of the Bowling
Green community. The opening of our 23rd plasma center is another step forward in our
commitment to better serve the thousands of patients worldwide whose lives are enhanced through plasma-derived medicines"
The total investment amounts to over $1.5 million in renovations of this newly constructed
facility and expects to add over 40 jobs to the local economy. Currently, there are employment opportunities available for
medical personnel and phlebotomists.
In addition to supporting the local economy through employment, the Biotest Plasma Center is actively recruiting local
residents to donate plasma and looking at ways to support the local community. Plasma donors contribute the much needed source
material used in the manufacture of plasma-derived medicines and are also compensated for their commitment. Grifols operates the
largest network of plasma donor centers in the world that includes over 200 centers in the United
States.
To learn more about Grifols, this new BPC plasma center, and the difference we make in the lives of patients and the
healthcare community, please visit www.grifols.com and
www.biotestplasma.com.
About Grifols
Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and
well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals
and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.
Grifols' three main divisions – Bioscience, Diagnostic and Hospital – develop, produce and market innovative products and
services that are available in more than 100 countries.
With a network of approximately 250 plasma donation centers, Grifols is a leading producer of plasma-derived medicines used to
treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a
comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital
Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that
automate drug compounding and control drug inventory.
Grifols is headquartered in Barcelona, Spain and has 20,000 employees in 30 countries.
In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to
advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.
The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).
SOURCE Grifols